Breast Density Assessment With Handheld Ultrasound Probe

A dense breast is the one a mammogram struggles to see through. Density is how much fibroglandular tissue the breast holds against fat: fat reads dark on a mammogram, dense tissue reads white, and a cancer reads white too, so it can be lost against a dense background. That blind spot is where ultrasound comes in, reading the dense tissue a mammogram cannot.

What breast density is

Breast density is the mix of two tissues in the breast. Fibroglandular tissue, the working part that makes and carries milk, is the firm component that shows up white. Fat is the loose filler around it. The ratio of the two is what density measures. A young woman tends to have dense breasts. Density falls with age, as fibroglandular tissue gives way to fat. Some women keep dense breasts well into later life.

Density is not the same thing as a lump. A nodule is a discrete object the reader measures and scores. Density is the make-up of the whole breast. Whether a breast holds a nodule has nothing to do with how dense it is. The category describes the background tissue, never a single finding within it.

Density is set by biology, outside the patient’s control. It runs in families. It is higher in younger women, in women on hormone therapy and in women with a lower body weight. It is a normal finding. It is common enough that close to half of all screened women have breasts dense enough to matter for their screening.

The four density categories

BI-RADS sorts breast density into four categories, A through D. Category A is almost entirely fatty, under 25 percent fibroglandular tissue. The mammogram sees through it well. Category B is scattered fibroglandular density, 25 to 50 percent dense. Category C is heterogeneously dense, 51 to 75 percent, where dense areas can hide a small mass. Category D is extremely dense, over 75 percent, where the density lowers what the mammogram can show.

The categories split the screened population in a known way. Around 10 percent of women fall in A, 40 percent in B, 40 percent in C and 10 percent in D. The two dense categories, C and D, together account for about half the screened population. The term dense breast points to the women in C or D. Those in A or B count as non-dense.

The mammogram is what the category is read from. The ultrasound scan does not set it. A radiologist assigns the category by eye, or a software tool measures it. The fifth edition of BI-RADS moved the call toward the masking question, how much the density could hide a cancer, ahead of the raw percentage of dense tissue. A small patch of dense tissue behind the nipple can hide more than a wider area spread thin.

Density is not fixed for life. It tends to fall after menopause, as the fibroglandular tissue thins. Hormone therapy can hold it up or push it higher again. A woman can move from category C to category B across a decade, or hold dense breasts throughout. This is why the category is read fresh at each mammogram and never carried over from an old report.

How density hides a cancer

The trouble with dense tissue is that it reads the same white as a cancer. A tumor on a mammogram shows as a white mass. In a fatty breast, that white mass stands out against the dark fat. In a dense breast, the white mass sits in a field of white. It can disappear into the background. This is masking. It is the first reason density matters on a report.

Masking shows in the numbers. A mammogram catches close to 98 percent of cancers in a fatty breast. In an extremely dense breast, that sensitivity can fall to around 30 percent. Two in three cancers can go unseen on the mammogram in the densest breasts. The cancer is present. The mammogram cannot separate it from the white tissue around it.

The clearest cost of masking is the interval cancer. This is a cancer found between two screening rounds, after a mammogram that read as clear. Interval cancers are more common in dense breasts, since masking lets a cancer hide until it grows large enough to feel. Catching those cancers earlier is the point of an added scan.

Newer mammography helps a little. Tomosynthesis, the three-dimensional form, takes the breast in thin slices and lowers the chance that normal tissue stacks into a false white. It cuts the summation effect. It does not erase masking in the densest breasts. A category D breast stays hard to read even on the three-dimensional study, which is why density still calls for another kind of imaging.

Masking changes what a clear result means. How much a clear mammogram reassures depends on the density behind it. The fatty breast gives a strong all-clear. At the extreme-density end, the same clear result leaves more room for a hidden cancer. It means less as the breast gets denser.

Density and cancer risk

Density hides cancer on the mammogram, the masking described above. It also raises the chance of a cancer in the first place. These are two separate effects. The risk effect holds even after the masking is accounted for. Dense tissue is more than a viewing problem. It is a risk factor in its own right. This effect appears across age groups and screening methods. The numbers come from large studies that compared cancer rates across the density categories. A fatty breast sets the baseline for the comparison. Scattered density raises the relative risk to around 2.0, with a confidence interval near 1.6 to 2.7. At the heterogeneously dense level the figure reaches about 2.8. For extremely dense breasts it sits close to 4.1, with the interval running from about 3.0 to 5.6. That puts a woman with extremely dense breasts at roughly four times the cancer risk of a woman with fatty breasts, with the upper estimate reaching near six times. The steps between the categories matter on their own. From scattered to heterogeneously dense, the risk is about 1.5 fold higher. The jump to extremely dense roughly doubles it again. The reason is partly that fibroglandular tissue is the tissue a cancer starts in, so more of it means more tissue where a cancer can begin. Density is one of the more common risk factors a woman can carry, since it is present in around half of women, far more than a family history or a single inherited gene. Density also shows up on the routine mammogram already being done, so it costs nothing extra to record. The risk sits alongside the masking. The two together make the dense breast the harder one to screen, since it both raises the odds of a cancer and lowers the odds of catching it on the mammogram. That pairing is why density has moved onto reports and into law. The size of the risk is steady across the large studies, which is why it now sits on the screening report and no longer in the research literature alone. A young woman with extremely dense breasts and a family history carries more than one risk factor at once. Her plan reflects all of them. The density alone does not make a diagnosis. It moves a woman up or down the scale that decides how closely she is watched and which extra tests she is offered. A density that is measured the same way each visit lets that scale hold steady over the years of repeated screening.

Why ultrasound helps a dense breast

Ultrasound reads a dense breast in a way the mammogram cannot. Dense tissue blocks the mammogram. Ultrasound sends sound through the tissue and reads it layer by layer. A cancer that disappeared into the white on the mammogram can show as a discrete dark mass on ultrasound, since a solid mass reflects sound in a way the tissue around it does not.

This is the case for supplemental screening. A woman with dense breasts and a clear mammogram can have an added ultrasound to look for what the mammogram missed. The yield is real. Supplemental ultrasound finds around 2 to 4 extra cancers per 1000 women screened. The ACRIN 6666 trial reported 4.2 per 1000 in the first round. The cancers found this way were small, near 10 millimeters, and few had reached the lymph nodes.

The extra scan brings more findings to work up. Ultrasound in a dense breast turns up benign nodules along with the cancers, so some women go to a follow-up or a biopsy that proves benign. Recall ran near 21 percent in the first ultrasound round of that trial. It settled toward 11 percent by the third round, as prior scans gave a baseline for comparison. The added early cancers are the reason the approach is widely accepted for dense breasts.

Two forms of ultrasound do this work. Handheld ultrasound, the kind a portable probe gives, lets the operator sweep the whole breast in real time and follow up any finding on the spot. It rests on the operator’s technique. Automated breast ultrasound runs a machine across the breast and records a volume for a radiologist to read later. Automated scanning gives a consistent, repeatable record. A handheld sweep keeps the live look that lets the operator press on a finding and adjust the angle. A portable probe brings that live form into the clinic.

Measuring the density

The density category is set by a reader or by a software tool. The older way is the visual read. A radiologist looks at the mammogram and places it in one of the four categories by eye. The visual call carries some reader-to-reader variation, since the line between heterogeneously dense and scattered is a judgment more than a fixed measurement.

Two readers can land one category apart.

The newer way is automated. Software such as Volpara or Quantra measures the fibroglandular tissue on the mammogram and reports a category or a volume figure by a consistent rule each time.

Area-based tools read the dense area on the flat image. Volume-based tools estimate the dense tissue through the depth of the breast. Automated reading removes some of the reader variation and gives a number that holds steady across visits.

Either way, the density is recorded on the report. The category goes with the mammogram result and informs the decision about supplemental screening. A consistent density call lets a woman and her doctor track the density over the years and plan the screening around it. A density that climbs over time can change the plan.

Density notification and the screening plan

Density has moved from a technical note to a patient’s right to know. In the United States, a federal rule that took effect on September 10, 2024, requires every mammogram report to tell the woman whether her breasts are dense. The notice tells a woman with dense breasts that the density makes the mammogram harder to read and raises her cancer risk. It points her to a conversation about extra imaging.

The plan that follows depends on the density and the rest of the risk picture. A woman at average risk with dense breasts may add an ultrasound to her mammogram. At high risk, with dense breasts on top, the usual step up is to MRI. The density is one input into a screening plan, weighed with family history, prior biopsies and the other risk factors. No single factor sets the plan on its own.

The handheld scan has a place in this plan. It can serve as the supplemental tool for a dense breast, run by the same operator who holds the mammogram report. It brings the added look to the clinic without a second machine or a second visit. The portable form lowers the barrier to the scan a dense breast needs.

Assessing density on a handheld unit

A handheld unit does not set the density category, which is read from the mammogram. Its job is the supplemental scan. The operator sweeps the dense breast in overlapping passes with a high-frequency linear probe, so no segment is skipped. A focal dark mass the mammogram could not show is visible against the brighter background.

About the Author

Julien Mercier

Senior R&D Engineer · Medical Ultrasound Transducer Development

Senior R&D Engineer with an M.S. in Applied Physics and over 15 years of experience in medical ultrasound transducer development, specializing in the design verification and performance testing of high-frequency imaging transducers. Currently leading the development and verification of the company’s next-generation high-frequency linear-array transducer, responsible for imaging performance evaluation and reliability analysis in preclinical testing. Brings extensive hands-on experience in piezoelectric element tuning, beamforming parameter optimization, and system-level performance testing.